Related Experiment Video

Updated: Jun 6, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Device therapy in hypertrophic cardiomyopathy

Roger Beadle1, Lynne Williams

  • 1University of Aberdeen, Aberdeen, AB25 2ZD, UK. rogerbeadle@hotmail.com

Expert Review of Cardiovascular Therapy
|November 27, 2010
PubMed

Insights

Diagnoses of hypertrophic cardiomyopathy are rising. Rigorous risk stratification is crucial for identifying high-risk patients, guiding decisions on implantable cardioverter-defibrillators to prevent sudden cardiac death while considering device complications.

Area of Science:

  • Cardiology
  • Genetics
  • Preventive Medicine

Background:

  • Increasing awareness and family screening are leading to more hypertrophic cardiomyopathy diagnoses.
  • Most patients have a low risk of sudden cardiac death, but high-risk individuals require careful management.
  • Implantable cardioverter-defibrillators are effective but carry risks and impact quality of life.

Purpose of the Study:

  • To highlight the importance of risk stratification in hypertrophic cardiomyopathy.
  • To discuss the role of implantable cardioverter-defibrillators in managing sudden cardiac death risk.
  • To emphasize the need for careful consideration of device implantation in high-risk patients.

Main Methods:

  • Review of current clinical practices and guidelines for hypertrophic cardiomyopathy.
  • Analysis of sudden cardiac death risk factors in hypertrophic cardiomyopathy patients.
  • Evaluation of the efficacy and complications associated with implantable cardioverter-defibrillators.

Main Results:

  • Hypertrophic cardiomyopathy diagnoses are increasing due to heightened awareness and screening.
  • Comprehensive risk factor stratification is essential for all patients.
  • Implantable cardioverter-defibrillators are effective for sudden cardiac death prevention but require careful patient selection.

Conclusions:

  • Ongoing risk stratification is vital for managing hypertrophic cardiomyopathy patients.
  • Implantable cardioverter-defibrillators should be implanted judiciously in high-risk individuals.
  • Balancing the benefits of sudden cardiac death prevention with potential device complications is key.

More Related Videos

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...